FDA Panel Votes Against Capricor's Duchenne Heart Disease Treatment

An advisory panel of the U.S. Food and Drug Administration (FDA) voted against approving Capricor Therapeutics' treatment for heart disease associated with Duchenne muscular dystrophy. According to Reuters, panel members determined that there was insufficient evidence regarding the treatment's efficacy and safety. Capricor's therapy aimed to address heart muscle weakness seen in Duchenne patients. However, the panel stated that data from clinical trials did not demonstrate a meaningful benefit in slowing disease progression. The FDA is known to generally follow panel recommendations. This development represents a significant hurdle in Capricor's regulatory approval process. While the company continues to emphasize the potential benefits of the treatment, investors are monitoring the impact of the decision on the stock. This is not investment advice.